Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 3/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8577314 | 0.88 | SCN5A (0.49) | SCN5ASCN9AGRM5HPGDALDH1A1 | |
| SCHEMBL12310865 | 0.77 | SCN9A (0.47) | SCN5ASCN9AGRM5 | |
| SCHEMBL13495499 | 0.76 | KDM4E (0.77) | SMN1; SMN2KDM4EHPGDALDH1A1MLYCD | |
| SCHEMBL12569604 | 0.76 | HPGD (0.74) | SMN1; SMN2GRM5KDM4EHPGDALDH1A1 | |
| SCHEMBL7909422 | 0.76 | SMN1; SMN2 (0.53) | SMN1; SMN2KDM4EHPGDALDH1A1MLYCD | |
| SCHEMBL3634940 | 0.75 | HPGD (0.60) | SMN1; SMN2HPGDALDH1A1USP2CYP3A4 | |
| SCHEMBL31387924 | 0.75 | HPGD (0.68) | KDM4EHPGDEGLN2ALDH1A1MLYCD | |
| SCHEMBL31387922 | 0.75 | HPGD (0.68) | KDM4EHPGDEGLN2ALDH1A1MLYCD | |
| SCHEMBL505097 | 0.74 | HCAR1 (0.53) | — | |
| SCHEMBL18734483 | 0.74 | HPGD (0.57) | SMN1; SMN2KDM4EHPGDALDH1A1MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2331518-A1 | NEW BRADYKININ B1 ANTAGONISTS | Evotec AG (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010020556-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | SCN5A 1356/4885SCN9A 1141/4885SMN1; SMN2 4510/4885 |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | SCN5A 1170/4885SCN9A 1091/4885SMN1; SMN2 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.